0.76
-0.029(-3.67%)
Currency In USD
| Previous Close | 0.79 |
| Open | 0.77 |
| Day High | 0.8 |
| Day Low | 0.75 |
| 52-Week High | 737.5 |
| 52-Week Low | 0.73 |
| Volume | 123,295 |
| Average Volume | 2.78M |
| Market Cap | 2.79M |
| PE | 0 |
| EPS | -6,321.5 |
| Moving Average 50 Days | 1.13 |
| Moving Average 200 Days | 63.87 |
| Change | -0.03 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of June 01, 2025 at a share price of $0.761. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0.04 as of June 01, 2025 at a share price of $0.761.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
GlobeNewswire Inc.
May 22, 2025 12:16 PM GMT
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program WARRINGTON, Pa.,
Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference
GlobeNewswire Inc.
May 19, 2025 12:00 PM GMT
Cardiogenic shock is a medically urgent condition and drug treatment innovation is desired by providers who treat the conditionWARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WI
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
GlobeNewswire Inc.
May 12, 2025 12:00 PM GMT
ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and reperfusionWARRINGTON, Pa., May 12, 2025 (GLOBE NEW